PA
EHC icon

PharVision Advisers’s Encompass Health EHC Stock Holding History

PharVision Advisers’s Portfolio EHC Stock Details EHC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-2,483
Closed -$264K – 271
2025
Q4 		$264K Buy
+2,483
New +$288K 0.13% 358
2025
Q3 		– Sell
-2,810
Closed -$345K – 699
2025
Q2 		$345K Buy
+2,810
New +$321K 0.5% 50
2025
Q1 		– Sell
-6,192
Closed -$572K – 341
2024
Q4 		$572K Buy
+6,192
New +$608K 0.48% 25

Other funds holding EHC

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return

PharVision Advisers's EHC Position: Q1 2026 in Review

PharVision Advisers sold out of Encompass Health (EHC) in Q1 2026, closing a stake of 2,483 shares — an estimated $264K sold.

PharVision Advisers first reported a position in EHC in Q4 2024 and held it in 3 quarters. The position peaked at $572K in Q4 2024. 577 funds tracked by Wall St. Rank hold EHC as of Q1 2026.

  • PharVision Advisers reported no remaining Encompass Health position as of Q1 2026 after selling out during the quarter.
  • PharVision Advisers sold 2,483 Encompass Health shares in Q1 2026, an estimated $264K.
  • PharVision Advisers first reported a position in Encompass Health in Q4 2024 and held it in 3 quarters.
  • PharVision Advisers's Encompass Health position peaked at $572K in Q4 2024.
  • 577 funds tracked by Wall St. Rank held Encompass Health as of Q1 2026.

Based on PharVision Advisers's 13F filing for Q1 2026, filed 22 Apr 2026.